
USD
$0.00
(0.00%
)At Close (As of Oct 24, 2025)
$88.36B
Market Cap
19.57
P/E Ratio
2.21
EPS
$46.87
52 Week High
$30.68
52 Week Low
HEALTHCARE
Sector
| Field | Value (GBP) |
|---|---|
| Gross Profit | $22B |
| Total Revenue | $31B |
| Cost Of Revenue | $9B |
| Costof Goods And Services Sold | $9B |
| Operating Income | $4B |
| Selling General And Administrative | $11B |
| Research And Development | $6.4B |
| Operating Expenses | $18B |
| Investment Income Net | - |
| Net Interest Income | -$603M |
| Interest Income | $60M |
| Interest Expense | $640M |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $2.6B |
| Income Before Tax | $3.5B |
| Income Tax Expense | $526M |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | $3B |
| Comprehensive Income Net Of Tax | - |
| Ebit | $4.1B |
| Ebitda | $6.7B |
| Net Income | $2.6B |
| Field | Value (GBP) |
|---|---|
| Total Assets | $59B |
| Total Current Assets | $17B |
| Cash And Cash Equivalents At Carrying Value | $3.7B |
| Cash And Short Term Investments | $3.7B |
| Inventory | $5.7B |
| Current Net Receivables | $6B |
| Total Non Current Assets | $42B |
| Property Plant Equipment | $10B |
| Accumulated Depreciation Amortization Ppe | - |
| Intangible Assets | $16B |
| Intangible Assets Excluding Goodwill | $16B |
| Goodwill | $7B |
| Investments | - |
| Long Term Investments | - |
| Short Term Investments | $21M |
| Other Current Assets | $1.6B |
| Other Non Current Assets | - |
| Total Liabilities | $46B |
| Total Current Liabilities | $22B |
| Current Accounts Payable | $3.5B |
| Deferred Revenue | - |
| Current Debt | - |
| Short Term Debt | $2.3B |
| Total Non Current Liabilities | $25B |
| Capital Lease Obligations | $1.1B |
| Long Term Debt | $14B |
| Current Long Term Debt | $2.2B |
| Long Term Debt Noncurrent | - |
| Short Long Term Debt Total | $17B |
| Other Current Liabilities | $15B |
| Other Non Current Liabilities | $6.1B |
| Total Shareholder Equity | $14B |
| Treasury Stock | - |
| Retained Earnings | $7.8B |
| Common Stock | $1.3B |
| Common Stock Shares Outstanding | $2.1B |
| Field | Value (GBP) |
|---|---|
| Operating Cashflow | $6.6B |
| Payments For Operating Activities | - |
| Proceeds From Operating Activities | - |
| Change In Operating Liabilities | - |
| Change In Operating Assets | - |
| Depreciation Depletion And Amortization | $2.6B |
| Capital Expenditures | $3B |
| Change In Receivables | - |
| Change In Inventory | -$294M |
| Profit Loss | - |
| Cashflow From Investment | -$1.2B |
| Cashflow From Financing | -$4.7B |
| Proceeds From Repayments Of Short Term Debt | - |
| Payments For Repurchase Of Common Stock | - |
| Payments For Repurchase Of Equity | - |
| Payments For Repurchase Of Preferred Stock | - |
| Dividend Payout | $2.4B |
| Dividend Payout Common Stock | $2.4B |
| Dividend Payout Preferred Stock | - |
| Proceeds From Issuance Of Common Stock | - |
| Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
| Proceeds From Issuance Of Preferred Stock | - |
| Proceeds From Repurchase Of Equity | $20M |
| Proceeds From Sale Of Treasury Stock | - |
| Change In Cash And Cash Equivalents | - |
| Change In Exchange Rate | - |
| Net Income | $3B |
| Field | Value (GBP) |
|---|---|
| Gross Profit | $22B |
| Total Revenue | $31B |
| Cost Of Revenue | $9B |
| Costof Goods And Services Sold | $9B |
| Operating Income | $4B |
| Selling General And Administrative | $11B |
| Research And Development | $6.4B |
| Operating Expenses | $18B |
| Investment Income Net | - |
| Net Interest Income | -$603M |
| Interest Income | $60M |
| Interest Expense | $640M |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $2.6B |
| Income Before Tax | $3.5B |
| Income Tax Expense | $526M |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | $3B |
| Comprehensive Income Net Of Tax | - |
| Ebit | $4.1B |
| Ebitda | $6.7B |
| Net Income | $2.6B |
| Field | Value |
|---|---|
| Ex Dividend Date | 2025-08-15 |
| Declaration Date | None |
| Record Date | None |
| Payment Date | None |
| Amount | 0.428118 |
Sector: HEALTHCARE
Industry: DRUG MANUFACTURERS - GENERAL
GlaxoSmithKline PLC (GSK) is a prominent global biopharmaceutical company headquartered in Brentford, UK, dedicated to improving health outcomes through its innovative pharmaceuticals, vaccines, and consumer healthcare products. With a focus on robust research and development, GSK aims to tackle significant global health challenges while maintaining a diverse product portfolio across multiple therapeutic areas. The company’s strategic initiatives and commitment to advancing medical science position it as a vital contributor to the global healthcare landscape, appealing to institutional investors seeking opportunities within the evolving biopharmaceutical industry.